454 A novel MDK targeted therapy for the treatment of endometrial cancer
Emily Aller, Alondra L Rodriguez Sanchez, Megharani Mahajan, Xue Yang, Paulina Ramirez, Panneerdoss Subbarayalu, Manjeet K Rao, Edward R Kost, Hareesh B Nair, Ratna K Vadlamudi, Suryavathi Viswanadhapalli · 2026
Read 454 A novel MDK targeted therapy for the treatment of endometrial cancer by Emily Aller, Alondra L Rodriguez Sanchez, Megharani Mahajan, Xue Yang, Paulina Ramirez, Panneerdoss Subbarayalu, Manjeet K Rao, Edward R Kost, Hareesh B Nair, Ratna K Vadlamudi, Suryavathi Viswanadhapalli (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13173001.txt.
Description
Emily Aller and co-authors develop a targeted drug for womb cancer in a conference report published in 2026. Endometrial cancer is rising fast in women under forty, and advanced cases respond poorly to current care. The team aimed at midkine, a growth factor that tumors of this type make in large amounts.
Using the protein's three-dimensional structure, they designed a small molecule, HBS-101, that binds midkine directly. Binding tests confirmed a tight grip. In cell tests the drug cut viability and colony growth at low doses and pushed cells toward death. It also suppressed two signaling pathways the cancer uses. Early animal work covered dosing, tolerance, and effect on tumors, and the drug worked in cells that resist standard chemotherapy.
Catalog record
| CREATOR | Emily Aller, Alondra L Rodriguez Sanchez, Megharani Mahajan, Xue Yang, Paulina Ramirez, Panneerdoss Subbarayalu, Manjeet K Rao, Edward R Kost, Hareesh B Nair, Ratna K Vadlamudi, Suryavathi Viswanadhapalli |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |